The global market for Choroidal Neovascularization Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Choroidal Neovascularization Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Choroidal Neovascularization Drug.

The Choroidal Neovascularization Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Choroidal Neovascularization Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Choroidal Neovascularization Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Choroidal Neovascularization Drug Market Report

Report Metric	Details
Report Name	Choroidal Neovascularization Drug Market
CAGR	5%
Segment by Type	AVMOC-001 BB-3 BBT-007 DG-3 Entolimod EWA-001 Others
Segment by Application	Clinic Hospital Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Cellphire, Inc., Chrysalis BioTherapeutics, Inc., Cleveland BioLabs, Inc., Cumberland Pharmaceuticals, Inc., Diffusion Pharmaceuticals Inc., Eli Lilly and Company, GNI Group Ltd., Humanetics Corporation, INSYS Therapeutics, Inc., Meabco A/S, Neumedicines Inc., Onconova Therapeutics, Inc., PharmaIN Corporation, Pluristem Therapeutics Inc., ProCertus BioPharm Inc., RDD Pharma Ltd., RedHill Biopharma Ltd., RxBio, Inc., Soligenix, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Choroidal Neovascularization Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Choroidal Neovascularization Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Choroidal Neovascularization Drug Market report?

Ans: The main players in the Choroidal Neovascularization Drug Market are Cellphire, Inc., Chrysalis BioTherapeutics, Inc., Cleveland BioLabs, Inc., Cumberland Pharmaceuticals, Inc., Diffusion Pharmaceuticals Inc., Eli Lilly and Company, GNI Group Ltd., Humanetics Corporation, INSYS Therapeutics, Inc., Meabco A/S, Neumedicines Inc., Onconova Therapeutics, Inc., PharmaIN Corporation, Pluristem Therapeutics Inc., ProCertus BioPharm Inc., RDD Pharma Ltd., RedHill Biopharma Ltd., RxBio, Inc., Soligenix, Inc.

What are the Application segmentation covered in the Choroidal Neovascularization Drug Market report?

Ans: The Applications covered in the Choroidal Neovascularization Drug Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the Choroidal Neovascularization Drug Market report?

Ans: The Types covered in the Choroidal Neovascularization Drug Market report are AVMOC-001, BB-3, BBT-007, DG-3, Entolimod, EWA-001, Others

1 Choroidal Neovascularization Drug Market Overview

1.1 Product Definition

1.2 Choroidal Neovascularization Drug by Type

1.2.1 Global Choroidal Neovascularization Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 AVMOC-001

1.2.3 BB-3

1.2.4 BBT-007

1.2.5 DG-3

1.2.6 Entolimod

1.2.7 EWA-001

1.2.8 Others

1.3 Choroidal Neovascularization Drug by Application

1.3.1 Global Choroidal Neovascularization Drug Market Value by Application (2024 VS 2031)

1.3.2 Clinic

1.3.3 Hospital

1.3.4 Others

1.4 Global Choroidal Neovascularization Drug Market Size Estimates and Forecasts

1.4.1 Global Choroidal Neovascularization Drug Revenue 2020-2031

1.4.2 Global Choroidal Neovascularization Drug Sales 2020-2031

1.4.3 Global Choroidal Neovascularization Drug Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Choroidal Neovascularization Drug Market Competition by Manufacturers

2.1 Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Choroidal Neovascularization Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Choroidal Neovascularization Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Choroidal Neovascularization Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Choroidal Neovascularization Drug, Product Type & Application

2.7 Global Key Manufacturers of Choroidal Neovascularization Drug, Date of Enter into This Industry

2.8 Global Choroidal Neovascularization Drug Market Competitive Situation and Trends

2.8.1 Global Choroidal Neovascularization Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Choroidal Neovascularization Drug Players Market Share by Revenue

2.8.3 Global Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Choroidal Neovascularization Drug Market Scenario by Region

3.1 Global Choroidal Neovascularization Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Choroidal Neovascularization Drug Sales by Region: 2020-2031

3.2.1 Global Choroidal Neovascularization Drug Sales by Region: 2020-2025

3.2.2 Global Choroidal Neovascularization Drug Sales by Region: 2026-2031

3.3 Global Choroidal Neovascularization Drug Revenue by Region: 2020-2031

3.3.1 Global Choroidal Neovascularization Drug Revenue by Region: 2020-2025

3.3.2 Global Choroidal Neovascularization Drug Revenue by Region: 2026-2031

3.4 North America Choroidal Neovascularization Drug Market Facts & Figures by Country

3.4.1 North America Choroidal Neovascularization Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Choroidal Neovascularization Drug Sales by Country (2020-2031)

3.4.3 North America Choroidal Neovascularization Drug Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Choroidal Neovascularization Drug Market Facts & Figures by Country

3.5.1 Europe Choroidal Neovascularization Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Choroidal Neovascularization Drug Sales by Country (2020-2031)

3.5.3 Europe Choroidal Neovascularization Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Choroidal Neovascularization Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Choroidal Neovascularization Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Choroidal Neovascularization Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Choroidal Neovascularization Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Choroidal Neovascularization Drug Market Facts & Figures by Country

3.7.1 Latin America Choroidal Neovascularization Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Choroidal Neovascularization Drug Sales by Country (2020-2031)

3.7.3 Latin America Choroidal Neovascularization Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Choroidal Neovascularization Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Choroidal Neovascularization Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Choroidal Neovascularization Drug Sales by Type (2020-2031)

4.1.1 Global Choroidal Neovascularization Drug Sales by Type (2020-2025)

4.1.2 Global Choroidal Neovascularization Drug Sales by Type (2026-2031)

4.1.3 Global Choroidal Neovascularization Drug Sales Market Share by Type (2020-2031)

4.2 Global Choroidal Neovascularization Drug Revenue by Type (2020-2031)

4.2.1 Global Choroidal Neovascularization Drug Revenue by Type (2020-2025)

4.2.2 Global Choroidal Neovascularization Drug Revenue by Type (2026-2031)

4.2.3 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2020-2031)

4.3 Global Choroidal Neovascularization Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Choroidal Neovascularization Drug Sales by Application (2020-2031)

5.1.1 Global Choroidal Neovascularization Drug Sales by Application (2020-2025)

5.1.2 Global Choroidal Neovascularization Drug Sales by Application (2026-2031)

5.1.3 Global Choroidal Neovascularization Drug Sales Market Share by Application (2020-2031)

5.2 Global Choroidal Neovascularization Drug Revenue by Application (2020-2031)

5.2.1 Global Choroidal Neovascularization Drug Revenue by Application (2020-2025)

5.2.2 Global Choroidal Neovascularization Drug Revenue by Application (2026-2031)

5.2.3 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2020-2031)

5.3 Global Choroidal Neovascularization Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Cellphire, Inc.

6.1.1 Cellphire, Inc. Company Information

6.1.2 Cellphire, Inc. Description and Business Overview

6.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio

6.1.5 Cellphire, Inc. Recent Developments/Updates

6.2 Chrysalis BioTherapeutics, Inc.

6.2.1 Chrysalis BioTherapeutics, Inc. Company Information

6.2.2 Chrysalis BioTherapeutics, Inc. Description and Business Overview

6.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio

6.2.5 Chrysalis BioTherapeutics, Inc. Recent Developments/Updates

6.3 Cleveland BioLabs, Inc.

6.3.1 Cleveland BioLabs, Inc. Company Information

6.3.2 Cleveland BioLabs, Inc. Description and Business Overview

6.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio

6.3.5 Cleveland BioLabs, Inc. Recent Developments/Updates

6.4 Cumberland Pharmaceuticals, Inc.

6.4.1 Cumberland Pharmaceuticals, Inc. Company Information

6.4.2 Cumberland Pharmaceuticals, Inc. Description and Business Overview

6.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio

6.4.5 Cumberland Pharmaceuticals, Inc. Recent Developments/Updates

6.5 Diffusion Pharmaceuticals Inc.

6.5.1 Diffusion Pharmaceuticals Inc. Company Information

6.5.2 Diffusion Pharmaceuticals Inc. Description and Business Overview

6.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio

6.5.5 Diffusion Pharmaceuticals Inc. Recent Developments/Updates

6.6 Eli Lilly and Company

6.6.1 Eli Lilly and Company Company Information

6.6.2 Eli Lilly and Company Description and Business Overview

6.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio

6.6.5 Eli Lilly and Company Recent Developments/Updates

6.7 GNI Group Ltd.

6.7.1 GNI Group Ltd. Company Information

6.7.2 GNI Group Ltd. Description and Business Overview

6.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio

6.7.5 GNI Group Ltd. Recent Developments/Updates

6.8 Humanetics Corporation

6.8.1 Humanetics Corporation Company Information

6.8.2 Humanetics Corporation Description and Business Overview

6.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio

6.8.5 Humanetics Corporation Recent Developments/Updates

6.9 INSYS Therapeutics, Inc.

6.9.1 INSYS Therapeutics, Inc. Company Information

6.9.2 INSYS Therapeutics, Inc. Description and Business Overview

6.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio

6.9.5 INSYS Therapeutics, Inc. Recent Developments/Updates

6.10 Meabco A/S

6.10.1 Meabco A/S Company Information

6.10.2 Meabco A/S Description and Business Overview

6.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Meabco A/S Choroidal Neovascularization Drug Product Portfolio

6.10.5 Meabco A/S Recent Developments/Updates

6.11 Neumedicines Inc.

6.11.1 Neumedicines Inc. Company Information

6.11.2 Neumedicines Inc. Description and Business Overview

6.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio

6.11.5 Neumedicines Inc. Recent Developments/Updates

6.12 Onconova Therapeutics, Inc.

6.12.1 Onconova Therapeutics, Inc. Company Information

6.12.2 Onconova Therapeutics, Inc. Description and Business Overview

6.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio

6.12.5 Onconova Therapeutics, Inc. Recent Developments/Updates

6.13 PharmaIN Corporation

6.13.1 PharmaIN Corporation Company Information

6.13.2 PharmaIN Corporation Description and Business Overview

6.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.13.4 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio

6.13.5 PharmaIN Corporation Recent Developments/Updates

6.14 Pluristem Therapeutics Inc.

6.14.1 Pluristem Therapeutics Inc. Company Information

6.14.2 Pluristem Therapeutics Inc. Description and Business Overview

6.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio

6.14.5 Pluristem Therapeutics Inc. Recent Developments/Updates

6.15 ProCertus BioPharm Inc.

6.15.1 ProCertus BioPharm Inc. Company Information

6.15.2 ProCertus BioPharm Inc. Description and Business Overview

6.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.15.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio

6.15.5 ProCertus BioPharm Inc. Recent Developments/Updates

6.16 RDD Pharma Ltd.

6.16.1 RDD Pharma Ltd. Company Information

6.16.2 RDD Pharma Ltd. Description and Business Overview

6.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.16.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio

6.16.5 RDD Pharma Ltd. Recent Developments/Updates

6.17 RedHill Biopharma Ltd.

6.17.1 RedHill Biopharma Ltd. Company Information

6.17.2 RedHill Biopharma Ltd. Description and Business Overview

6.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.17.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio

6.17.5 RedHill Biopharma Ltd. Recent Developments/Updates

6.18 RxBio, Inc.

6.18.1 RxBio, Inc. Company Information

6.18.2 RxBio, Inc. Description and Business Overview

6.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.18.4 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio

6.18.5 RxBio, Inc. Recent Developments/Updates

6.19 Soligenix, Inc.

6.19.1 Soligenix, Inc. Company Information

6.19.2 Soligenix, Inc. Description and Business Overview

6.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2020-2025)

6.19.4 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio

6.19.5 Soligenix, Inc. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Choroidal Neovascularization Drug Industry Chain Analysis

7.2 Choroidal Neovascularization Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Choroidal Neovascularization Drug Production Mode & Process Analysis

7.4 Choroidal Neovascularization Drug Sales and Marketing

7.4.1 Choroidal Neovascularization Drug Sales Channels

7.4.2 Choroidal Neovascularization Drug Distributors

7.5 Choroidal Neovascularization Drug Customer Analysis

8 Choroidal Neovascularization Drug Market Dynamics

8.1 Choroidal Neovascularization Drug Industry Trends

8.2 Choroidal Neovascularization Drug Market Drivers

8.3 Choroidal Neovascularization Drug Market Challenges

8.4 Choroidal Neovascularization Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Cellphire

Chrysalis BioTherapeutics, Inc.

Cleveland BioLabs, Inc.

Cumberland Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc.

Eli Lilly and Company

GNI Group Ltd.

Humanetics Corporation

INSYS Therapeutics Inc

Meabco A/S

Neumedicines Inc

Onconova Therapeutics Inc

PharmaIN Corporation

Pluristem Therapeutics Inc

ProCertus BioPharm Inc.

RDD Pharma Ltd.

RedHill Biopharma Ltd

RxBio Inc

Soligenix Inc

List of Tables

Table 1. Global Choroidal Neovascularization Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Choroidal Neovascularization Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Choroidal Neovascularization Drug Market Competitive Situation by Manufacturers in 2024

Table 4. Global Choroidal Neovascularization Drug Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Choroidal Neovascularization Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Choroidal Neovascularization Drug Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Choroidal Neovascularization Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Choroidal Neovascularization Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Choroidal Neovascularization Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Choroidal Neovascularization Drug, Product Type & Application

Table 12. Global Key Manufacturers of Choroidal Neovascularization Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Choroidal Neovascularization Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Choroidal Neovascularization Drug as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Choroidal Neovascularization Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Choroidal Neovascularization Drug Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Choroidal Neovascularization Drug Sales Market Share by Region (2020-2025)

Table 19. Global Choroidal Neovascularization Drug Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Choroidal Neovascularization Drug Sales Market Share by Region (2026-2031)

Table 21. Global Choroidal Neovascularization Drug Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2020-2025)

Table 23. Global Choroidal Neovascularization Drug Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2026-2031)

Table 25. North America Choroidal Neovascularization Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Choroidal Neovascularization Drug Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Choroidal Neovascularization Drug Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Choroidal Neovascularization Drug Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Choroidal Neovascularization Drug Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Choroidal Neovascularization Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Choroidal Neovascularization Drug Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Choroidal Neovascularization Drug Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Choroidal Neovascularization Drug Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Choroidal Neovascularization Drug Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Choroidal Neovascularization Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Choroidal Neovascularization Drug Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Choroidal Neovascularization Drug Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Choroidal Neovascularization Drug Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Choroidal Neovascularization Drug Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Choroidal Neovascularization Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Choroidal Neovascularization Drug Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Choroidal Neovascularization Drug Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Choroidal Neovascularization Drug Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Choroidal Neovascularization Drug Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Choroidal Neovascularization Drug Sales (K Pcs) by Type (2020-2025)

Table 51. Global Choroidal Neovascularization Drug Sales (K Pcs) by Type (2026-2031)

Table 52. Global Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025)

Table 53. Global Choroidal Neovascularization Drug Sales Market Share by Type (2026-2031)

Table 54. Global Choroidal Neovascularization Drug Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Choroidal Neovascularization Drug Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2020-2025)

Table 57. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2026-2031)

Table 58. Global Choroidal Neovascularization Drug Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Choroidal Neovascularization Drug Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Choroidal Neovascularization Drug Sales (K Pcs) by Application (2020-2025)

Table 61. Global Choroidal Neovascularization Drug Sales (K Pcs) by Application (2026-2031)

Table 62. Global Choroidal Neovascularization Drug Sales Market Share by Application (2020-2025)

Table 63. Global Choroidal Neovascularization Drug Sales Market Share by Application (2026-2031)

Table 64. Global Choroidal Neovascularization Drug Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Choroidal Neovascularization Drug Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2020-2025)

Table 67. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2026-2031)

Table 68. Global Choroidal Neovascularization Drug Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Choroidal Neovascularization Drug Price (USD/Pcs) by Application (2026-2031)

Table 70. Cellphire, Inc. Company Information

Table 71. Cellphire, Inc. Description and Business Overview

Table 72. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. Cellphire, Inc. Choroidal Neovascularization Drug Product

Table 74. Cellphire, Inc. Recent Developments/Updates

Table 75. Chrysalis BioTherapeutics, Inc. Company Information

Table 76. Chrysalis BioTherapeutics, Inc. Description and Business Overview

Table 77. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product

Table 79. Chrysalis BioTherapeutics, Inc. Recent Developments/Updates

Table 80. Cleveland BioLabs, Inc. Company Information

Table 81. Cleveland BioLabs, Inc. Description and Business Overview

Table 82. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product

Table 84. Cleveland BioLabs, Inc. Recent Developments/Updates

Table 85. Cumberland Pharmaceuticals, Inc. Company Information

Table 86. Cumberland Pharmaceuticals, Inc. Description and Business Overview

Table 87. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product

Table 89. Cumberland Pharmaceuticals, Inc. Recent Developments/Updates

Table 90. Diffusion Pharmaceuticals Inc. Company Information

Table 91. Diffusion Pharmaceuticals Inc. Description and Business Overview

Table 92. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product

Table 94. Diffusion Pharmaceuticals Inc. Recent Developments/Updates

Table 95. Eli Lilly and Company Company Information

Table 96. Eli Lilly and Company Description and Business Overview

Table 97. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. Eli Lilly and Company Choroidal Neovascularization Drug Product

Table 99. Eli Lilly and Company Recent Developments/Updates

Table 100. GNI Group Ltd. Company Information

Table 101. GNI Group Ltd. Description and Business Overview

Table 102. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. GNI Group Ltd. Choroidal Neovascularization Drug Product

Table 104. GNI Group Ltd. Recent Developments/Updates

Table 105. Humanetics Corporation Company Information

Table 106. Humanetics Corporation Description and Business Overview

Table 107. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. Humanetics Corporation Choroidal Neovascularization Drug Product

Table 109. Humanetics Corporation Recent Developments/Updates

Table 110. INSYS Therapeutics, Inc. Company Information

Table 111. INSYS Therapeutics, Inc. Description and Business Overview

Table 112. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 113. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product

Table 114. INSYS Therapeutics, Inc. Recent Developments/Updates

Table 115. Meabco A/S Company Information

Table 116. Meabco A/S Description and Business Overview

Table 117. Meabco A/S Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 118. Meabco A/S Choroidal Neovascularization Drug Product

Table 119. Meabco A/S Recent Developments/Updates

Table 120. Neumedicines Inc. Company Information

Table 121. Neumedicines Inc. Description and Business Overview

Table 122. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 123. Neumedicines Inc. Choroidal Neovascularization Drug Product

Table 124. Neumedicines Inc. Recent Developments/Updates

Table 125. Onconova Therapeutics, Inc. Company Information

Table 126. Onconova Therapeutics, Inc. Description and Business Overview

Table 127. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 128. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product

Table 129. Onconova Therapeutics, Inc. Recent Developments/Updates

Table 130. PharmaIN Corporation Company Information

Table 131. PharmaIN Corporation Description and Business Overview

Table 132. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 133. PharmaIN Corporation Choroidal Neovascularization Drug Product

Table 134. PharmaIN Corporation Recent Developments/Updates

Table 135. Pluristem Therapeutics Inc. Company Information

Table 136. Pluristem Therapeutics Inc. Description and Business Overview

Table 137. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 138. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product

Table 139. Pluristem Therapeutics Inc. Recent Developments/Updates

Table 140. ProCertus BioPharm Inc. Company Information

Table 141. ProCertus BioPharm Inc. Description and Business Overview

Table 142. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 143. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product

Table 144. ProCertus BioPharm Inc. Recent Developments/Updates

Table 145. RDD Pharma Ltd. Company Information

Table 146. RDD Pharma Ltd. Description and Business Overview

Table 147. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 148. RDD Pharma Ltd. Choroidal Neovascularization Drug Product

Table 149. RDD Pharma Ltd. Recent Developments/Updates

Table 150. RedHill Biopharma Ltd. Company Information

Table 151. RedHill Biopharma Ltd. Description and Business Overview

Table 152. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 153. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product

Table 154. RedHill Biopharma Ltd. Recent Developments/Updates

Table 155. RxBio, Inc. Company Information

Table 156. RxBio, Inc. Description and Business Overview

Table 157. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 158. RxBio, Inc. Choroidal Neovascularization Drug Product

Table 159. RxBio, Inc. Recent Developments/Updates

Table 160. Soligenix, Inc. Company Information

Table 161. Soligenix, Inc. Description and Business Overview

Table 162. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 163. Soligenix, Inc. Choroidal Neovascularization Drug Product

Table 164. Soligenix, Inc. Recent Developments/Updates

Table 165. Key Raw Materials Lists

Table 166. Raw Materials Key Suppliers Lists

Table 167. Choroidal Neovascularization Drug Distributors List

Table 168. Choroidal Neovascularization Drug Customers List

Table 169. Choroidal Neovascularization Drug Market Trends

Table 170. Choroidal Neovascularization Drug Market Drivers

Table 171. Choroidal Neovascularization Drug Market Challenges

Table 172. Choroidal Neovascularization Drug Market Restraints

Table 173. Research Programs/Design for This Report

Table 174. Key Data Information from Secondary Sources

Table 175. Key Data Information from Primary Sources

Table 176. Authors List of This Report

List of Figures

Figure 1. Product Picture of Choroidal Neovascularization Drug

Figure 2. Global Choroidal Neovascularization Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Choroidal Neovascularization Drug Market Share by Type: 2024 & 2031

Figure 4. AVMOC-001 Product Picture

Figure 5. BB-3 Product Picture

Figure 6. BBT-007 Product Picture

Figure 7. DG-3 Product Picture

Figure 8. Entolimod Product Picture

Figure 9. EWA-001 Product Picture

Figure 10. Others Product Picture

Figure 11. Global Choroidal Neovascularization Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 12. Global Choroidal Neovascularization Drug Market Share by Application: 2024 & 2031

Figure 13. Clinic

Figure 14. Hospital

Figure 15. Others

Figure 16. Global Choroidal Neovascularization Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Choroidal Neovascularization Drug Market Size (2020-2031) & (US$ Million)

Figure 18. Global Choroidal Neovascularization Drug Sales (2020-2031) & (K Pcs)

Figure 19. Global Choroidal Neovascularization Drug Average Price (USD/Pcs) & (2020-2031)

Figure 20. Choroidal Neovascularization Drug Report Years Considered

Figure 21. Choroidal Neovascularization Drug Sales Share by Manufacturers in 2024

Figure 22. Global Choroidal Neovascularization Drug Revenue Share by Manufacturers in 2024

Figure 23. Global 5 and 10 Largest Choroidal Neovascularization Drug Players: Market Share by Revenue in Choroidal Neovascularization Drug in 2024

Figure 24. Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 25. Global Choroidal Neovascularization Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 26. North America Choroidal Neovascularization Drug Sales Market Share by Country (2020-2031)

Figure 27. North America Choroidal Neovascularization Drug Revenue Market Share by Country (2020-2031)

Figure 28. U.S. Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Canada Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2020-2031)

Figure 31. Europe Choroidal Neovascularization Drug Revenue Market Share by Country (2020-2031)

Figure 32. Germany Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. France Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. U.K. Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Italy Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Russia Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Region (2020-2031)

Figure 38. Asia Pacific Choroidal Neovascularization Drug Revenue Market Share by Region (2020-2031)

Figure 39. China Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Japan Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. South Korea Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. India Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Australia Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Taiwan Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Indonesia Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Thailand Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Malaysia Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Philippines Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America Choroidal Neovascularization Drug Sales Market Share by Country (2020-2031)

Figure 50. Latin America Choroidal Neovascularization Drug Revenue Market Share by Country (2020-2031)

Figure 51. Mexico Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Country (2020-2031)

Figure 55. Middle East and Africa Choroidal Neovascularization Drug Revenue Market Share by Country (2020-2031)

Figure 56. Turkey Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Saudi Arabia Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. UAE Choroidal Neovascularization Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. Global Sales Market Share of Choroidal Neovascularization Drug by Type (2020-2031)

Figure 60. Global Revenue Market Share of Choroidal Neovascularization Drug by Type (2020-2031)

Figure 61. Global Choroidal Neovascularization Drug Price (USD/Pcs) by Type (2020-2031)

Figure 62. Global Sales Market Share of Choroidal Neovascularization Drug by Application (2020-2031)

Figure 63. Global Revenue Market Share of Choroidal Neovascularization Drug by Application (2020-2031)

Figure 64. Global Choroidal Neovascularization Drug Price (USD/Pcs) by Application (2020-2031)

Figure 65. Choroidal Neovascularization Drug Value Chain

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Single-Port Vitrectomy Cutter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-13L12609

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Eye Ultrasound Biomicroscope Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32B20021

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Plano-Convex Laser Lenses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-38C19846

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Heated Eye Masks Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2H20253

Thu Nov 27 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions